• Tempus AI recently reported clinical validation results showing that its Immune Profile Score (IPS) test more accurately predicts outcomes for patients receiving immune checkpoint inhibitors than conventional biomarkers like tumor mutational burden, microsatellite instability, and PD-L1, while also confirming record contract value of over US$1.10 billions and expanding its AI pathology offerings.
• An interesting insight is that IPS identified subgroups of microsatellite-stable colorectal and rare cancer patients who may benefit from immunotherapy but could have been missed using traditional biomarker tests alone, underscoring Tempus AI’s focus on turning existing genomic data into more actionable treatment guidance.
• We will now examine how the Immune Profile Score’s superior predictive performance could influence Tempus AI’s broader investment narrative.

Trump's oil boom is here - pipelines are primed to profit. Discover the 22 US stocks riding the wave.

What Is Tempus AI's Investment Narrative?

To own Tempus AI, you really have to believe that turning its genomic and pathology data into clinically trusted AI tests can support a durable, high-value business despite current losses and a rich sales multiple. The latest Immune Profile Score validation fits that thesis neatly, reinforcing the idea that Tempus can extract more value from data it is already generating with xT and xR. In the near term, that kind of clinical proof could help the company cross-sell IPS, deepen pharma data contracts and support its record US$1.10 billions in total contract value, but it does not on its own resolve the key tensions the stock faces: ongoing unprofitability, insider selling, a Price-to-Sales ratio well above peers and a share price that has sold off sharply even as analysts’ targets remain much higher.

But there is one risk in particular that Tempus shareholders cannot afford to ignore. Despite retreating, Tempus AI's shares might still be trading above their fair value and there could be some more downside. Discover how much.

Exploring Other Perspectives

Thirty-one fair value views from the Simply Wall St Community span roughly US$25 to US$180 per share, reflecting very different expectations for Tempus’ path to profitability and how much weight to place on emerging diagnostics like IPS and Paige Predict. Taken together with the recent price slide and premium sales multiple, this spread in community views underlines why you may want to compare several risk and catalyst scenarios before forming your own conviction on the stock.

Explore 31 other fair value estimates on Tempus AI - why the stock might be worth over 3x more than the current price!

Build Your Own Tempus AI Narrative

Disagree with this assessment? Create your own narrative in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Tempus AI research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Tempus AI research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Tempus AI's overall financial health at a glance.

Contemplating Other Strategies?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

• AI is about to change healthcare. These 105 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• These 14 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.
• Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 32 best rare earth metal stocks of the very few that mine this essential strategic resource.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.